Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02918539 · ClinicalTrials.gov registry record
Registry of Amyloid Positive Patients for Alzheimer's Disease Drug Research Trials
A clinical trial, sponsored by Avid Radiopharmaceuticals.
- Completed
- Registry status
- 317
- Enrollment target
NCT02918539 is a clinical trial that has completed, run by Avid Radiopharmaceuticals. The registered enrollment target is 317 participants.
The verdict
NCT02918539 has completed, sponsored by Avid Radiopharmaceuticals.
- COMPLETED
- Registry status
- 317 participants
- Enrollment target
Study Summary
This registry will be used to identify patients who have etiology diagnosed or suspected to be Alzheimer's disease and positive amyloid scans, and have indicated their interest in being contacted for an Eli Lilly and Company (Lilly) Alzheimer's Disease drug research trial.
Interventions
- DRUG florbetapir F 18 PET scan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 317 participants |
| Start Date | 2016-10 |
| Est. Completion | 2017-10-18 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02918539
The ClinicalTrials.gov registry entry for NCT02918539 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 317 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Avid Radiopharmaceuticals, which has 42 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which florbetapir F 18 PET scan is the first listed.
NCT02918539 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02918539 about?
NCT02918539 is a clinical study titled "Registry of Amyloid Positive Patients for Alzheimer's Disease Drug Research Trials". This registry will be used to identify patients who have etiology diagnosed or suspected to be Alzheimer's disease and positive amyloid scans, and have indicated their interest in being contacted for an Eli Lilly and Company (Lilly) Alzheimer's Disease drug research trial.
What is the current status of trial NCT02918539?
This trial is currently completed. The enrollment target is 317 participants. The study started on 2016-10. Estimated completion is 2017-10-18.
What interventions are being tested in trial NCT02918539?
The interventions under investigation include: florbetapir F 18 PET scan (DRUG).
Who is sponsoring clinical trial NCT02918539?
This trial is sponsored by Avid Radiopharmaceuticals, which has 42 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.